hCGβ-TT-IRES-CD40L真核表达载体的构建  

Construction of Beta-hCG-TT-IRES-CD40L Eukaryotic Expression Vector

作　　者：卢明[1,2] 王其龙[1] 刘静[1] 刘胜武[1] 

机构地区：[1]武汉大学医学院免疫学系,湖北武汉430071 [2]广州市达安临床检验中心有限公司,广东广州510080

出　　处：《武汉大学学报（医学版）》2010年第2期259-262,280,共5页Medical Journal of Wuhan University

摘　　要：目的:构建含有分子佐剂CD40L的真核表达质粒hCGβ-TT,以提高hCGβ的免疫原性。方法:用分段PCR的方法构建了hCGβ-TT,然后插入双元真核表达质粒IRES的A位点,将CD40L插入pIRES的B位点构建hCGβ-TT-IRES-CD40L。结果:经测序所克隆的基因hCGβ-TT和CD40L序列正确。结论:利用分子佐剂CD40L与hCGβ-TT的连接,构建了hCGβ-TT-IRES-CD40L真核细胞表达质粒,为检测hCGβDNA免疫避孕疫苗的免疫原性及抗生育作用奠定了基础。Objective：To construct hCGβ-TT eukaryotic expression plasmid containing CD40L molecular adjuvant to enhance the immunogenicity of hCGβ. Methods： The eukaryotic expression plasmid of hCGβ-TT was constructed and inserted into the dual IRES eukaryotic expression plasmid in locus A, and CD40L was inserted into locus B to generate hCGβ-TT-IRES-CD40L eukaryotic expression plasmid. Results： hCGβ-TT and CD40L were identified by cloning and sequencing of hCGβ-TT-IRES-CD40L plasmid. Conclusion： The hCGβ-TT-IRES-CD40L eukaryotic expression plasmid was established successfully for the further study of contraceptive vaccine hCGβ DNA.

关 键 词：人绒毛膜促性腺激素β CD40L 基因疫苗 真核表达载体pIRES 

分 类 号：R782[医药卫生—口腔医学]